Sugi Predict

Sugi Predict / Compounds / SCHEMBL5149459

SCHEMBL5149459

SCHEMBL5149459

Brc1cccc(C2CCCCC2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 1/20 0.54
▸ DRD1 P21728 1/20 0.54
▸ DRD4 P21917 1/20 0.54
▸ DRD5 P21918 1/20 0.54
▸ DRD3 P35462 1/20 0.54
▸ KMO O15229 1/20 0.53
▸ KDM1A O60341 3/20 0.50
▸ HDAC4 P56524 2/20 0.50
▸ HDAC2 Q92769 1/20 0.50
▸ HDAC8 Q9BY41 1/20 0.50
▸ CYP11B2 P19099 1/20 0.46
▸ HTR2A P28223 1/20 0.43
▸ HTR2C P28335 1/20 0.43
▸ HTR2B P41595 1/20 0.43
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ RORC P51449 1/20 0.40
▸ RCOR1 Q9UKL0 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ ACMSD Q8TDX5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31518368 1.00 DRD2 (0.54) DRD2DRD1DRD4DRD5DRD3
SCHEMBL30919606 0.98 DRD2 (0.55) DRD2DRD1DRD4DRD5DRD3
SCHEMBL8414747 0.98 DRD2 (0.55) DRD2DRD1DRD4DRD5DRD3
SCHEMBL3976082 0.94 DRD2 (0.55) DRD2DRD1DRD4DRD5DRD3
SCHEMBL30169622 0.94 DRD2 (0.55) DRD2DRD1DRD4DRD5DRD3
SCHEMBL957833 0.89 KDM1A (0.55) DRD2DRD1DRD4DRD5DRD3
SCHEMBL29427010 0.89 KDM1A (0.55) DRD2DRD1DRD4DRD5DRD3
Iodide SCHEMBL5548757 0.87 KDM1A (0.53) DRD2DRD1DRD4DRD5DRD3
SCHEMBL5667650 0.87 KMO (0.64) DRD2DRD3KMOHDAC4HDAC2
SCHEMBL669730 0.87 KMO (0.64) DRD2DRD3KMOHDAC4HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102603497-B 1-alkoxy-4-[4-(4-alkyl cyclohexyl) phenyl]-2, 3-difluorobenzene and synthetic method thereof CHINA SYNCHEM TECHNOLOGY CO LTD 2013-11-27 — — CN claimed
CN-102603497-A 1-alkoxy-4-[4-(4-alkyl cyclohexyl) phenyl]-2, 3-difluorobenzene and synthetic method thereof CHINA SYNCHEM TECHNOLOGY CO LTD 2012-07-25 — — CN claimed
CN-117659017-B TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof 北京华益健康药物研究中心 2026-05-15 — — CN disclosed
US-12595243-B2 Modulators of extracellular signal-regulated kinase GEN1E LIFESCIENCES INC. (US) 2026-04-07 — — US disclosed
EP-4618755-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2025-09-24 — — EP disclosed
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC. 2025-05-01 — — US disclosed
WO-2025085745-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC. (US) 2025-04-24 — — WO disclosed
WO-2024107746-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES (US) 2024-05-23 — — WO disclosed
CN-117659017-A TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof 北京华益健康药物研究中心 2024-03-08 — — CN disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 — — WO disclosed
CN-106715414-B With 2 adrenaline excitant of β and the active new bicyclic derivatives of M3 muscarinic antagonist 阿尔米雷尔有限公司 2019-08-30 — — CN disclosed
CN-106715414-A New bicyclic derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities 阿尔米雷尔有限公司 2017-05-24 — — CN disclosed
CN-102603497-B 1-alkoxy-4-[4-(4-alkyl cyclohexyl) phenyl]-2, 3-difluorobenzene and synthetic method thereof CHINA SYNCHEM TECHNOLOGY CO LTD 2013-11-27 — — CN disclosed
CN-102603497-A 1-alkoxy-4-[4-(4-alkyl cyclohexyl) phenyl]-2, 3-difluorobenzene and synthetic method thereof CHINA SYNCHEM TECHNOLOGY CO LTD 2012-07-25 — — CN disclosed
EP-1515945-A4 METHOD FOR MAKING ARYL HYDRAZINES AND SUBSTITUTED INDOLES RHODIA PHARMA SOLUTION INC FOR (US) 2007-07-18 — — EP disclosed
EP-1515945-A2 METHOD FOR MAKING ARYL HYDRAZINES AND SUBSTITUTED INDOLES Rhodia Pharma Solution Inc., (formally Rhodia Chirex Inc.) (US) 2005-03-23 — — EP disclosed
WO-2004000218-A2 METHOD FOR MAKING ARYL HYDRAZINES AND SUBSTITUTED INDOLES RHODIA PHARMA SOLUTIONS INC., (FORMALLY RHODIA CHIREX INC.) (US) 2003-12-31 — — WO disclosed
US-6489512-B1 REACTING AROMATIC COMPOUND BEARING ACTIVATED CARBON ATOM AND HYDRAZONE IN PRESENCE OF TRANSITION METAL CATALYST TO FORM ARYL HYDRAZONE, HYDROLYZING TO FORM ARYL HYDRAZINE, CYCLIZING IN PRESENCE OF ACID CATALYST TO FORM SUBSTITUTED INDOLE RHODIA CHIREX INC. 2002-12-03 — — US disclosed
US-3992536-A SEDATIVES AND MUSCLE RELAXANTS BOEHRINGER INGELHEIM GMBH (DT) 1976-11-16 — — US disclosed
US-3931185-A SEDATIVES, MUSCLE RELAXANT BOEHRINGER INGELHEIM GMBH (DT) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE MAP3K20, MAP3K6, CDC42BPG DRD2 4857/4885DRD1 4882/4885DRD4 4881/4885
US-12595243-B2 Modulators of extracellular signal-regulated kinase CDC42BPG, GRK3, ERBB2 DRD2 4100/4885DRD1 4360/4885DRD4 4486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.